Evommune Initiates Phase 2B Clinical Trial Of Mrgprx2 Inhibitor Evo756 In Migraine Prophylaxis
EVMN•Phase 2B trial begins for Evo756 in migraine prophylaxis
Evommune Inc. EVMN.N:
- Evommune initiates phase 2B clinical trial of MRGPRX2 inhibitor Evo756 in migraine prophylaxis
- Evommune said top-line data from the phase 2B trial are expected in 2027
